Benzinga | Nov 23, 2020 09:07AM EST

Halozyme Therapeutics Raises FY2020 Sales Guidance from $250M-$260M to $265M-$275M

Halozyme Therapeutics (NASDAQ:HALO) raises FY2020 sales outlook from $250.00 million-260.00 million to $265.00 million-275.00 million.Halozyme Therapeutics (NASDAQ:HALO) raises FY2020 sales outlook from $250.00 million-260.00 million to $265.00 million-275.00 million.